Shingo Nakamura

Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA.

Cygnus, Inc. develops and manufactures glucose-monitoring devices. The company develops devices that provide data to individuals and physicians to enable them to manage diabetes. It was founded in 1985 and is headquartered in San Francisco, CA.

Trellis Bioscience, Inc. is discovers and develops novel human antibody therapeutics. It provides the discovery and development of therapeutic antibodies from human B cells. The firm develops the CellSpot antibody discovery platform, which enables the identification of antibodies directly from human blood. The company was founded by Lawrence Kauvar and Stote Ellsworth in 1998 and is headquartered in South San Francisco, CA.

Raven Biotechnologies, Inc. engages in the development of antibody therapeutics for the treatment for cancer, autoimmune disorders and infectious diseases. Its products are used in treatment of gastrointestinal, lung, colon, pancreatic, prostate, breast, brain, and ovarian cancer. The company was founded in 1999 and is headquartered in South San Francisco, CA.

Abmaxis Inc. develops pharmaceutical drugs. The company discovers and optimizes monoclonal antibody (mAb) products for human therapeutics and diagnostics. It has developed antibody engineering technology platform, Abmaxis in-silico Immunization (AISIM TM), which they are used for building an internal product pipeline and collaboration with global biotech and pharmaceutical partners. The company was founded in 2000 and is located in Santa Clara, CA.

Calliditas Therapeutics Suisse SA engages in the development of NOX therapies. Its platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes, which amplify multiple disease processes such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company was founded Chihiro Yabe, Robert A. Clark, David Lambeth, and Karl-Heinz Krause in 2006 and is headquartered in Geneva, Switzerland.

Banyu Pharmaceutical Co. Ltd. produces and distributes pharmaceutical products. It researches, develops, manufactures, sells, and imports and exports ethical drugs in Japan. Banyu Pharmaceutical was founded in 1915 and is headquartered in Tokyo, Japan.

Smith College opened in 1875 with 14 students. Today, Smith is among the largest women’s colleges in Northampton, MA, with students from 48 states and 72 countries. The college remains strongly committed to the education of women at the undergraduate level, but Smith admits both men and women as graduate students.

Global Factory, Inc. provides collaborative manufacturing execution systems. The firm's software gather, organize & analyze demand, production & quality data from various sources and monitor key indicators & execute business processes to control, manage & optimize distributed manufacturing operations. The company was founded in 1999 and is headquartered in Santa Clara, CA.

Mitsui & Co. Global Investment, Inc. (Mitsui & Co. Global Investment) is a venture capital subsidiary of Mitsui Ventures founded in 1999. The firm is headquartered in Menlo Park, California.

La Jolla Institute for Allergy & Immunology is a non-profit organization located in La Jolla, CA. The private company focuses on immunology research and aims to unravel the complexities of the immune system to tackle an array of diseases such as asthma, cancer, COVID-19, type 1 diabetes, and Parkinson's. The company is home to three research centers that focus on autoimmune conditions, cancer, and infectious diseases. The company offers various services such as bioinformatics, clinical studies, cryo-em, flow cytometry, histopathology, immunometabolism, microscopy & histology, and next-generation sequencing. The company also provides licensing opportunities and initiatives. The company was founded by Steve Pontell and is currently led by Erica Saphire as the CEO.

PROMETHERA Biosciences SA discovers, develops and commercializes cell therapy products to treat liver diseases. It operates as a pharmaceutical company that develops treatment based on allogeneic adult stem cell technology. The firm’s technology platform is based on a newly discovered cell type, isolated from normal human adult liver tissue: Heterologous Human Adult Liver Progenitor Cells (HHALPC). The company was founded by Etienne Marc Sokal and Eric Halioua on February 12, 2009 and is headquartered in Mont-Saint-Guibert, Belgium.

A-CUBE, Inc. develops novel antibodies. It utilizes silico algorithms and to discover novel druggable targets suitable for developing human therapeutic interventions, including next generation drugs for commercially proven targets. The company was founded by Nobuyuki Ota is headquartered in Belmont, CA.

NapaJen Pharma, Inc. develops drug delivery technology solutions through cellular transport pathways. Its products include lead platform and drug delivery. The firm specializes in the development of novel drug delivery systems by utilizing natural transport pathways whose cells are used to move molecular cargo into themselves and across internal compartments. The company was founded by Dr. Kazuo Sakurai and Hironori Ando in December 2004 and is headquartered in Burlingame, CA.

Nexvet Australia Pty Ltd. operates as a global clinical-stage biopharmaceutical company that develops and distributes medicines for companion animals. The firm focuses on transforming the therapeutic market by developing and commercializing novel biologic therapies, including products derived from its PETization technology. PETization is designed to rapidly create monoclonal antibodies that are recognized as “self” by a patient’s immune system. The company was founded by Mark Heffernan, Christopher Nigel Brown and David Gearing in February 2010 and is headquartered in Melbourne, Australia.

Miyako Capital KK (Miyako Capital) is an Independent Private Equity/Venture Capital firm founded in 2013 by Satoshi Yamaguchi and Hiroaki Okahashi. Miyako Capital KK is headquartered in Kyoto.

DCI Partners KK (DCI Partners) is a venture arm of Daiwa Corporate Investment Co., Ltd. founded in 2014. The firm is headquartered in Tokyo, Japan.

Part of Kaken Pharmaceutical Co., Ltd., ARTham Therapeutics, Inc. is a pharmaceutical company based in Yokohama, Japan. The Japanese company's mission is to deliver "medicines that matter" to improve patient health and contribute to enhanced quality of life through the development of innovative disease-modifying medicines. The company was founded by Sham Nikam, Naoto Uemura, and has been led by CEO Hiroshi Nagabukuro since 2018. ARTham Therapeutics was acquired by Kaken Pharmaceutical Co., Ltd. on December 13, 2021 for $111.95 million.

Junten Bio Co. Ltd. is a Japanese company founded in 2018 that engages in research and development of cell and regenerative medicines. The company is based in Chuo-ku, Japan.